Announced
Completed
Financials
Tags
neurological diseases
Single Bidder
pharmaceuticals
Majority
Acquisition
Pharmaceuticals
Domestic
medicines
Public
Friendly
United States
Completed
Synopsis
Supernus Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, completed the acquisition of Adamas Pharmaceuticals, an innovative medicines producer, that reduces the burden of neurological diseases on patients, caregivers and society, for $450m. "This acquisition represents a significant step to further build a strong and diverse Parkinson’s disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases. We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI’s growth momentum so that more patients can benefit from access to Adamas’ innovative neurological therapies," Jack Khattar, Supernus Pharmaceuticals President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.